

[Generate Collection](#)[Print](#)

Search Results - Record(s) 1 through 39 of 39 returned.

-
- ☐ 1. [20070280949](#). 12 Jul 04. 06 Dec 07. Combination Therapy for Gastroenteric Diseases Caused by Microorganisms. Alfa; Michelle. 424/157.1; A61K39/395 20060101 A61P1/00 20060101
-
- ☐ 2. [20070065461](#). 20 Sep 06. 22 Mar 07. Immunogenic capsule composition for use as a vaccine component against *campylobacter jejuni*. Guerry; Patricia, et al. 424/234.1; A61K39/02 20060101
-
- ☐ 3. [20070020736](#). 06 Jun 06. 25 Jan 07. Efficient production of oligosaccharides using metabolically engineered microorganisms. Samain; Eric. 435/85; 435/193 435/252.3 435/252.33 435/471 514/54 536/23.2 536/53 A61K31/739 20070101 C07H21/04 20060101 C08B37/00 20060101 C12N1/21 20070101 C12N15/74 20060101 C12N9/10 20060101 C12P19/28 20060101
-
- ☐ 4. [20060270618](#). 12 Dec 02. 30 Nov 06. Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases. Bevec; Dorian. 514/44; 424/85.6 435/6 A61K38/21 20070101 A61K48/00 20070101 C12Q1/68 20070101 C40B30/06 20070101 C40B40/08 20070101
-
- ☐ 5. [20060165728](#). 30 Jul 03. 27 Jul 06. *Campylobacter* glycans and glycopeptides. Young; Noel Martin, et al. 424/234.1; 435/34 530/395 536/53 A61K39/02 20060101 C07K14/205 20060101 C08B37/00 20060101 C12Q1/04 20060101
-
- ☐ 6. [20050221284](#). 29 Dec 04. 06 Oct 05. Heteropolymer complexes and methods for their use. Taylor, Ronald P., et al. 435/5; 424/144.1 530/388.22 C12Q001/70 A61K039/395 C07K016/28.
-
- ☐ 7. [20050182243](#). 11 Jan 05. 18 Aug 05. Membrane scaffold proteins. Sligar, Stephen G., et al. 530/350; C07K014/47.
-
- ☐ 8. [20050118199](#). 07 Oct 04. 02 Jun 05. Process for covalently conjugating polysaccharides to microspheres or biomolecules. Esser, Mark T., et al. 424/244.1; 424/490 530/395 536/53 536/55.3 A61K039/385 A61K039/09 C07K014/195 C08B037/00.
-
- ☐ 9. [20030232750](#). 18 Oct 02. 18 Dec 03. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics. Krieger, Timothy J., et al. 514/12; 514/13 514/15 514/16 530/324 530/325 530/326 530/327 530/328 A61K038/17 A61K038/10 A61K038/08 C07K007/08 C07K007/06.
-
- ☐ 10. [20020128381](#). 25 Apr 02. 12 Sep 02. Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces. Jakobsen, Mogens Havsteen, et al. 525/54.2; 536/53 C08B037/00.
-
- ☐ 11. [20020035061](#). 27 Feb 98. 21 Mar 02. COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS. KRIEGER, TIMOTHY J., et al. 514/2; 424/184.1 514/17 514/18 514/19 514/20 A61K038/10 A61K038/05 A61K038/06 A61K038/07.
-
- ☐ 12. [6902743](#). 06 Apr 98; 07 Jun 05. Therapeutic treatment and prevention of infections with a bioactive material(s) encapsulated within a biodegradable-bio-compatible polymeric matrix.
-

Setterstrom; Jean A., et al. 424/489; 424/451 424/470 424/482 424/490. A61K009/14 A61K039/40 A61K009/48 A61K009/26 A61K009/16 .

☐ 13. [6881549](#). 25 Apr 02; 19 Apr 05. Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces. Jakobsen; Mogens Havsteen, et al. 435/7.35; 436/529 536/123.1 536/17.2 536/18.5. G01N033/569 G01N033/573 G01N033/544 C07H001/00 C07H015/00 .

☐ 14. [6551599](#). 16 Mar 01; 22 Apr 03. Monoclonal antibodies against campylobacter jejuni and campylobacter coli outer membrane antigens. Mandrell; Robert E., et al. 424/234.1; 424/130.1 424/141.1 424/150.1 424/164.1 435/70.2 435/70.21 530/387.1 530/387.5 530/388.1 530/388.2 530/388.4. A61K039/02 .

☐ 15. [6399336](#). 15 Jan 98; 04 Jun 02. Practical in vitro sialylation of recombinant glycoproteins. Paulson; James C., et al. 435/97; 435/15 435/183 435/193 435/220 435/252.3 435/4 435/41 435/7.2. C12P001/00 C12P021/06 C12P019/00 G01N033/53 C12Q001/00 .

☐ 16. [6348318](#). 03 Apr 98; 19 Feb 02. Methods for concentrating ligands using magnetic particles. Valkirs; Gunars E.. 435/7.1; 435/7.2 435/7.32 435/7.35 435/7.37 435/7.92 435/7.93 435/7.94 435/975 436/518 436/526 436/806 436/824. G01N033/543 G01N033/553 G01N033/569 .

☐ 17. [6262029](#). 13 Aug 99; 17 Jul 01. Chemically modified saponins and the use thereof as adjuvants. Press; Jeffery B., et al. 514/26; 424/184.1 424/204.1 424/234.1 514/23 536/18.6 536/5. A61K031/70 A61K039/00 C07H015/24 .

☐ 18. [6080725](#). 13 Apr 99; 27 Jun 00. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof. Marciani; Dante J.. 514/26; 424/184.1 514/25 536/4.1 536/5. A61K031/705 A61K039/00 .

☐ 19. [6057115](#). 16 Jun 95; 02 May 00. Process for producing GM2 specific antibodies. Ritter; Gerd, et al. 435/7.23; 435/7.32 436/543 436/547. G01N033/574 G01N033/53 .

☐ 20. [5854007](#). 24 Apr 97; 29 Dec 98. Process for producing GM1 specific antibodies. Ritter; Gerd, et al. 435/7.23; 436/547 530/387.7 530/388.4 530/388.8 530/389.5. G01N033/574 G01N033/53 .

☐ 21. [WO2007038122A2](#). 20 Sep 06. 05 Apr 07. IMMUNOGENIC CAPSULE COMPOSITION FOR USE AS A VACCINE COMPONENT AGAINST CAMPYLOBACTER JEJUNI. GUERRY, PATRICIA, et al.

☐ 22. [WO009700445A1](#). 11 Jun 96. 03 Jan 97. PROCESS FOR PRODUCING GM2 SPECIFIC ANTIBODIES. RITTER, GERD, et al. G01N033/53; G01N033/531 G01N033/569 G01N033/574.

☐ 23. [US 20070065461 A1](#). Immunogenic composition useful as vaccine component for protection against diarrhea caused by campylobacter jejuni bacteria is composed of Campylobacter jejuni capsule polysaccharide polymer from Campylobacter jejuni strains. BAQAR S, et al.

☐ 24. [US 20070020736 A1](#). Producing oligosaccharide comprises culturing microorganism comprising bifunctional Campylobacter jejuni sialyltransferase in medium with lactose and sialylic acid. SAMAIN E.

☐ 25. [WO 2006130832 A2](#). Pharmaceutical composition for modulating e.g., bacterial cell growth,

contains excipient, and anti-infective and immunomodulatory compound. DEZIEL E, et al.

☐ 26. [WO 2006119987 A2](#). New recombinant N-glycosylated protein, useful for preparing a medicament for the therapeutic and/or prophylactic vaccination of a subject. AEBI M, et al.

☐ 27. [US 20050182243 A1](#). Artificial membrane scaffold protein which assembles into particle in aqueous solution, useful for stabilizing hydrophobic or partially hydrophobic molecules (preferably proteins such cytochrome P450 or gp120 of HIV) in nanoscale particle. BAYBURT T, et al.

☐ 28. [US 20050118199 A1](#). Coupling a polysaccharide to a microsphere or biomolecule comprises use of 4-(4,6-dimethoxy(1,3,5)triazin-2-yl)-4-methyl-morpholinium chloride. ESSER M T, et al.

☐ 29. [WO 2005005481 A2](#). New pharmaceutical composition comprising polyclonal antibodies directed against at least one enteric pathogen, e.g. species of Salmonella, Vibrio or Clostridium, useful for treating gastrointestinal illnesses. ALFA M.

☐ 30. [WO 2004070002 A2](#). Decreasing infection of cell by virus, HIV, influenza A or Ebola, comprises interfering with activity or expression of host proteins or activity of host nucleic acids such as Rab9, AXL receptor tyrosine kinase, and Beta-chimerin. HODGE T, et al.

☐ 31. [WO 2004041310 A1](#). Synthesizing chemoselectively carbohydrate dendrimer conjugate having carbohydrate residue and immunomodulating substance, by identifying chemoselective and carbohydrate residue, and binding residues to dendrimer. BOAS U, et al.

☐ 32. [WO 2004013151 A2](#). New heptasaccharide compound useful for preventing campylobacter infections and for treating a disease caused by campylobacter pathogens. BRISSON J, et al.

☐ 33. [WO 2004002495 A1](#). Therapeutic composition useful for treatment of e.g. diarrhea comprises purified fraction of compounds which are or contain oligosaccharide sequence of pathogen receptors e.g. lactosylceramide receptor. ABUL-MILH M, et al.

☐ 34. [WO 02074942 A2](#). New glycosyltransferases from Campylobacter, useful for synthesizing gangliosides and ganglioside mimetics, and in studying the pathogenesis mechanisms of organisms that synthesize ganglioside mimetics. GILBERT M, et al.

☐ 35. [US 20020028215 A1](#). Novel vaccine for preventing, treating infectious diseases caused by virus, fungi, protozoa and bacteria, has a carrier strain having membrane vesicle of a microorganism integrated into cell surface of carrier strain. BEVERIDGE T J, et al.

☐ 36. [WO 0200851 A2](#). Novel Helicobacter pylori DD-heptosyl transferase polypeptide and polynucleotide, useful for treating diseases associated with Helicobacter pylori infection e.g. gastric ulcer and gastritis. ALTMAN E, et al.

☐ 37. [WO 0046379 A1](#). Novel glycosyltransferase polypeptides and polynucleotides useful for biosynthesis of ganglioside and ganglioside mimics, as diagnostic reagents and as immunogen for producing antibodies. GILBERT M, et al.

☐ 38. [WO 0036419 A1](#). Immobilizing polysaccharides with keto-carboxy group to solid surface e.g. for detection of bacterial infections from Gram-negative bacteria. BOAS U, et al.

☐ 39. [WO 9313797 A2](#). Vaccine comprising bacterial lipo-polysaccharide conjugated to a protein

for immunisation against cholera. GUPTA R K, et al.

[Generate Collection](#)[Print](#)

Term	Documents
JEJUNI	3102
JEJUNIS	7
(5 AND JEJUNI).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	39
(L5 AND JEJUNI).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	39

[Prev Page](#)[Next Page](#)[Go to Doc#](#)